News Quantified

TNXP – tonix pharmaceuticals holding corp. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals (NASDAQ:TNXP) was upgraded by analysts at Wall Str

Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by analysts at Wall S

Tonix prices 615,025 shares at $16.26 in registered direct offering [Yahoo! Finance]

4.7%

IN-LINE

1.3%

MISS

5.8%

BEAT

5.8%

BEAT

Form SCHEDULE 13G/A Tonix Pharmaceuticals Filed by: VANGUARD GROUP INC

Form SCHEDULE 13G/A Tonix Pharmaceuticals Filed by: BlackRock, Inc.

Form SCHEDULE 13G Tonix Pharmaceuticals Filed by: Point72 Asset Management, L.P.

Form 8-K Tonix Pharmaceuticals For: Dec 29

Form 424B5 Tonix Pharmaceuticals

Top News Gainers

2/26 Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800) 80.0%

3/20 Form 8-K Tonix Pharmaceuticals For: Mar 19 70.2%

12/11 Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL 22.2%

9/5 Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 19.7%

2/4 Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences 18.1%

5/21 Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology 16.0%

11/15 Tonix Pharmaceuticals Prices $9.0 Million Public Offering 15.4%

2/28 Form 424B5 Tonix Pharmaceuticals 15.3%

3/23 Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit 15.1%

1/24 Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL 14.8%

Top News Decliners

2/5 Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD -48.5%

2/7 Form EFFECT Tonix Pharmaceuticals -39.5%

2/27 Form 4 Tonix Pharmaceuticals For: Feb 25 Filed by: MORRIS JESSICA EDGAR -37.6%

11/4 Form 8-K Tonix Pharmaceuticals For: Nov 04 -31.9%

3/24 Form 8-K Tonix Pharmaceuticals For: Mar 24 -26.0%

11/15 Form EFFECT Tonix Pharmaceuticals -25.0%

11/20 Tonix Pharma up 12% after hours on advancement of TNX-102 SL in AUD [Seeking Alpha] -22.7%

1/7 Tonix Pharmaceuticals to Present at Biotech Showcase 2020 -20.5%

7/15 Form S-1/A Tonix Pharmaceuticals -19.3%

11/25 Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference -18.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day